Evestra is pursuing multiple research projects, targeting areas of high medical need.
Fertility control products are the largest sub-segment in the female health area, offering significant innovation potential on the drug delivery and new chemical entity side. Evestra is actively pursuing the following target indications:
Preterm birth is a significantly underserved indication in female health, affecting around 12% of pregnant women. Evestra is actively pursuing two drug delivery projects with known progestins that show higher efficacy than standard products in animal models.
Endometriosis and Fibroids effect about 10% of the fertile female population. Although these diseases are not life threatening, there is a high medical need for an effective treatment. Meso-progestin and selected progestin modifications have shown significant efficacy.
Evestra is actively researching a potent partial agonistic anti-progestin (meso-progestin) with strong anti-ovulatory properties that would effect an extended and safe treatment of these diseases.
Hormone Dependent Breast Cancer
Breast cancer is the most prominent cancer in women. A larger proportion of these tumors are steroid hormone dependent. For these tumors, an anti-hormone therapy with aromatase inhibitors is a very effective treatment with relatively mild side effects.
Anti-progestins have shown significant efficacy in the treatment of breast cancer in animal models and women.
Evestra has generated proprietary anti-progestins that show the highest in vitro activity in the T47D breast cancer cell line. Pharmacological studies are on-going to determine the best therapeutic approach and target group.
Hormone Replacement Therapy (HRT)
Vaginal Ring, Estrogen/Progestin
Progestin only Vaginal Ring
Progesterone-Based Formulation for Preterm Birth
Vaginal Ring for Preterm Labor
6 Month Injectable Fertility Control
2nd Generation Mesoprogestin
New Estradiol for Fertility Control
Antiprogestin for Hormone Dependent Breast Cancer